Abstract
Heart disease and cancer are the leading causes of death in older adults. Many first-line cancer treatments have the potential for cardiotoxicity. Age-related risk factors, pre-existing cardiac disease, and a high prevalence of comorbidities are reasons for increased cardiotoxicity in older adults. Concerns regarding cardiotoxicity may lead to frailty bias and undertreatment, resulting in suboptimal outcomes. There is an urgent need for geriatric-specific evidence and guidelines to help tailor care for this vulnerable group. A multi-disciplinary approach based on close collaboration between oncologists, cardiologists, and geriatricians, among other specialist clinicians is essential.
Original language | English (US) |
---|---|
Pages (from-to) | 308-314 |
Number of pages | 7 |
Journal | Journal of Geriatric Oncology |
Volume | 8 |
Issue number | 4 |
DOIs | |
State | Published - Jul 2017 |
Bibliographical note
Funding Information:This article was supported by the National Institutes of Health grant K23HL132011-01 and the University of Minnesota Clinical and Translational Science Institute KL2 Scholars Career Development Program Award (National Institutes of Health grant KL2TR000113-05), both to Dr. Chetan Shenoy.
Publisher Copyright:
© 2017 Elsevier Inc.
Keywords
- Cardio-oncology
- Cardiotoxic treatments
- Cardiotoxicity
- Geriatrics
- Older adult